Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Cindy Houwen; Nico van Lisdonk; Jelle Bolier; Michelle van Eekeren; Mandy van Gaalen; Aline van Herk; Zaïd Paula; Natasja Peters; Martijn den Reijer; Kelly Mertens; Khoa T.D. Thai

doi:10.1016/j.diagmicrobio.2023.115970

Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Cindy Houwen
, Nico van Lisdonk
, Jelle Bolier
, Michelle van Eekeren
, Mandy van Gaalen
, Aline van Herk
, Zaïd Paula
, Natasja Peters
, Martijn den Reijer
, Kelly Mertens
, Khoa T.D. Thai^*

^*Corresponding author for this work

Star-SHL Medical Diagnostic Center

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

Original language	English
Article number	115970
Journal	Diagnostic Microbiology and Infectious Disease
Volume	106
Issue number	4
DOIs	https://doi.org/10.1016/j.diagmicrobio.2023.115970
Publication status	Published - Aug 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diagmicrobio.2023.115970

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124101/pdf/main.pdf

Cite this

Houwen, C., van Lisdonk, N., Bolier, J., van Eekeren, M., van Gaalen, M., van Herk, A., Paula, Z., Peters, N., den Reijer, M., Mertens, K., & Thai, K. T. D. (2023). Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV. Diagnostic Microbiology and Infectious Disease, 106(4), Article 115970. https://doi.org/10.1016/j.diagmicrobio.2023.115970

@article{343300917ca440f2b3fca4b59bb21d1d,

title = "Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV",

abstract = "We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex{\texttrademark} SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex{\texttrademark} RV Master Assay, Allplex{\texttrademark} SARS-CoV-2 fast MDx Assay (LAMP) and Aptima{\texttrademark} SARS-CoV-2/Flu Assay (RT-TMA). The assays{\textquoteright} performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8\% and 100\% with extremely good agreements (κ ≥ 86.8 \%). The Aptima{\texttrademark} SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.",

author = "Cindy Houwen and \{van Lisdonk\}, Nico and Jelle Bolier and \{van Eekeren\}, Michelle and \{van Gaalen\}, Mandy and \{van Herk\}, Aline and Za{\"i}d Paula and Natasja Peters and \{den Reijer\}, Martijn and Kelly Mertens and Thai, \{Khoa T.D.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = aug,

doi = "10.1016/j.diagmicrobio.2023.115970",

language = "English",

volume = "106",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

Houwen, C, van Lisdonk, N, Bolier, J, van Eekeren, M, van Gaalen, M, van Herk, A, Paula, Z, Peters, N, den Reijer, M, Mertens, K & Thai, KTD 2023, 'Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV', Diagnostic Microbiology and Infectious Disease, vol. 106, no. 4, 115970. https://doi.org/10.1016/j.diagmicrobio.2023.115970

TY - JOUR

T1 - Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

AU - Houwen, Cindy

AU - van Lisdonk, Nico

AU - Bolier, Jelle

AU - van Eekeren, Michelle

AU - van Gaalen, Mandy

AU - van Herk, Aline

AU - Paula, Zaïd

AU - Peters, Natasja

AU - den Reijer, Martijn

AU - Mertens, Kelly

AU - Thai, Khoa T.D.

PY - 2023/8

Y1 - 2023/8

N2 - We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

AB - We evaluated the diagnostic performance of 4 commercially NAAT for detecting SARS-CoV-2 RNA, Influenza type A/B virus and RSV. Included tests were the Allplex™ SARS-CoV-2 fast PCR Assay (RNA extraction-free), Allplex™ RV Master Assay, Allplex™ SARS-CoV-2 fast MDx Assay (LAMP) and Aptima™ SARS-CoV-2/Flu Assay (RT-TMA). The assays’ performance characteristics were determined using nasopharyngeal swabs from 270 patients with suspected SARS-CoV-2 infection. A total of 215 SARS-CoV-2 positive, 55 negative nasopharyngeal swabs and 19 bacteria strains were included. The sensitivities and specificities for detecting SARS-CoV-2, Influenza type A virus and RSV ranged between 81.8% and 100% with extremely good agreements (κ ≥ 86.8 %). The Aptima™ SARS-CoV-2/Flu Assay introduced a new result parameter, that is, TTime. Here, we showed that TTime may be used as a surrogate for Ct-value. We concluded that all assays assessed in this study can be used for routine detection of SARS-CoV-2, Influenza type A virus and RSV.

UR - https://www.scopus.com/pages/publications/85161275838

U2 - 10.1016/j.diagmicrobio.2023.115970

DO - 10.1016/j.diagmicrobio.2023.115970

M3 - Article

C2 - 37290260

AN - SCOPUS:85161275838

SN - 0732-8893

VL - 106

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

M1 - 115970

ER -

Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this